Welcome to TRD Consulting – your trusted partner in regulatory toxicology and nonclinical drug development and chemical safety.
I’m Dr. Ramesh Subramani, US board-certified and European Registered Toxicologist, an Independent Toxicology Consultant and Regulatory Toxicologist with over two decades of global experience in the pharmaceutical, biotech, and chemical industries. As a qualified Veterinarian (DVM) and a certified regulatory toxicologist (DABT, ERT, UKRT, RAC (US), DSP), I bring in-depth scientific, regulatory, and strategic expertise to support your toxicological evaluations of pharmaceuticals, medical devices and chemicals.
TRD Consulting is a global nonclinical consulting firm delivering high-quality toxicology and pharmacology services to the pharmaceutical, biotech, medical device, and chemical industries. Leveraging expertise in Toxicological Research and Development (TRD), We specialize in Drug Discovery, New Drug Development (IND/NDA/BLA), Generic Drug Development, 505(b)(2) Formulations, Toxicology Evaluation and Risk Assessment, Safety Assessment of Chemicals.
As an independent regulatory toxicologist and Nonclinical consulting firm, our primary focus is to provide technical and regulatory support for both new and existing products. We pride ourselves on delivering expertise that is effective, flexible, reliable, and timely—helping clients navigate complex regulatory pathways with confidence and compliance.
Pharmaceutical, biotech and chemical companies requiring toxicology safety/risk assessments and regulatory strategy
CROs seeking expert oversight for GLP study and compliance
Regulatory affairs teams preparing for global submissions including IND, NDA, ANDA, BLA and more
Chemical manufacturers requiring safety evaluations for REACH or EPA compliance
Years Experience
Projects Completed
Customers
Certifications
Providing scientific and regulatory insights to support early-stage compound selection, lead optimization, and IND-enabling studies.
Expert design, review, and interpretation of GLP-compliant in vitro and in vivo toxicology studies, reducing risk and enhancing data quality.
Strategic nonclinical development roadmaps for IND, NDA, BLA, and international regulatory filings (US FDA, EMA, DCGI, ECHA, EFSA, MHRA, BfArM, ANVISA, and more).
Scientific justification and qualification of impurities, degradants, and excipients in compliance with global regulatory expectations.